Abstract
A series of imidazo[4,5-c]quinoline derivatives(12a—12m) was synthesized with 2-amino-5-bromobenzoic acid and 4-nitrophenylacetonitrile as starting materials, 6-bromo-4-chloro-3-nitroquinoline as intermediate and Suzuki reaction and closure of the imidazolinone ring with triphosgene as key steps. The structures of the key intermediate and target compounds were confirmed by means of 1H NMR, 13C NMR and HRMS. These compounds show an interesting kinase profile as dual PI3K/mTOR tool compounds.
Similar content being viewed by others
References
Kang S., Bader A. G., Vogt P. K., Proc. Natl. Acad. Sci., 2005, 102(3), 802
Brown J. B., Cheresh P., Goretsky T., Managlia E., Grimm G. R., Ryu H., Zadeh M., Dirisina R., Barrett T. A., Infection and Immunity, 2011, 79(5), 1863
Cully M., You H., Levine A. J., Mak T. W., Nat. Rev. Cancer, 2006, 6(3), 184
Treins C., Warne P. H., Magnuson M. A., Pende M., Downward J., Oncogene, 2010, 29(7), 1003
Suire S., Coadwell J., Ferguson G. J., Davidson K., Hawkins P., Stephens L., Curr. Biol., 2005, 15(6), 566
Laplante M., Sabatini D. M., Cell, 2012, 149(2), 274
Shapiro G. I., Rodon J., Bedell C., Kwak E. L., Baselga J., Brana I., Pandya S. S., Scheffold C., Laird A. D., Nguyen L. T., Xu Y., Egile C., Edelman G., Clin. Cancer Res., 2014, 20(1), 233
Ma B. B. Y., Lui V. W. Y., Hui E. P., Lau C. P. Y., Ho K., Ng M. H. L., Cheng S. H., Tsao S. W., Chan A. T. C., Invest. New Drugs, 2010, 28(4), 413
Elicabe M. M., Yin D. L., Hadaczek P., Zhai Y. Y., Forsayeth J., Bankiewicz K. S., J. Neurooncol., 2012, 108(1), 53
Raynaud F. I., Eccles S. A., Patel S., Alix S., Box G., Chuckowree I. S., Folkes A. J., Gowan S., Brandon A. D. H., Stefano F. D., Hayes A., Henley A. T., Lensun L., Pergl-Wilson G. H., Robson A., Saghir N., Zhyvoloup P., McDonald E., Sheldrake P., Shuttleworth S., Va-lenti M., Wan N. C., Clarke P. A., Workman P., Mol. Cancer Ther., 2009, 8(7), 1725
Brunner-Kubath C., Shabbir W., Saferding V., Wagner R., Singer C. F., Valent P., Berger W., Marian B., Zielinski C. C., Grusch M., Grunt T. W., Breast Cancer Res. Treat., 2011, 129(2), 387
Nyfeler B., Chen Y., Li X.Y., Pinzon-Ortiz M., Wang Z., Reddy A., Pradhan E., Das R., Lehar J., Schlegel R., Finan P. M., Cao Z. A., Murphy L. O., Huang A., PLoS One, 2012, 7(11), 488
Baumann P., Mandl-Webber S., Oduncu F., Schmidmaier R., Exp. Cell Res., 2009, 315(3), 485
Stauffer F., Maira S. M., Furet P., Bioorg. Med. Chem. Lett., 2008, 18(3), 1027
Maira S. M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., Brachmann S., Chene P., Pover A. D., Schoemaker K., Fabbro D., Gabrie D., Simonen M., Murphy L., Finan P., Sellers W., Echeverri C., Mol. Cancer Ther., 2008, 7(7), 1851
Zhang X. M., Wang E. S., Niu S. X., Guo J., Dai Z. L., Zheng N., Du Z. J., Ji Q., Li Q. Y., Liang T., Imidazole Quinoline Derivatives, Pharmaceutical Compositions and Uses Thereof, CN103833752A, 2012
Zhang X. M., Ji Q., Wang L., Gao C. M., Wang E. S., Du Z. J., Gong L. L., Chen B., Imidazole Derivatives, Pharmaceutical Compositions and Uses Thereof, CN104447740A, 2014
Gerster J. F., Lindstrom K. J., Miller R. L., Tomai M. A., Birmachu W., Bomersine S. N., Gibson S. J., Imbertson L. M., Jacobson J. R., Knafla R. T., Maye P. V., Nikolaides N., Oneyemi F. Y., Parkhurst G. J., Pecore S. E., Reiter M. J., Scribner L. S., Testerman T. L., Thompson N. J., Wagner T. L., Weeks C. E., Andre J. D., Lagain D., Bastard Y., Lupu M., J. Med. Chem., 2005, 48(10), 3481
Bellina F., Carpita A., Rossi R., Synthesis, 2004, 15, 2419
Tawada H., Harcourt M., Kawamura N., Masahiro K., Ishikawa E., Sugiyama Y., Ikeda H., Meguro K., J. Med. Chem., 1994, 37(13), 2079
Zhang W. J., Li Z., Zhou M., Wu F., Hou X. Y., Luo H., Liu H., Han X., Yan G. Y., Ding Z. Y., Li R., Bioorg. Med. Chem. Lett., 2014, 24(3), 799
Suneel M. B., Hulawale Y., Paramasivan S., Hariharan S., Process For the Preparation Of Substituted Imidazo[4,5-c]quinoline Compounds, Intermediates and Polymorphs Thereof, WO145369A1, 2015
Li X., Dong Q., Chen Y., Wang B., Bai D. D., Imidazo Quinoline De-rivative and Medicinal Salt Thereof, Perparation Method Thereof and Use in Medicine Thereof, WO053273 A1, 2013
Schiaffo C. E., Shi C., Xiong Z. M., Olin M., Ohlfest J. R., Aldrich C. C., Ferguson D. M., J. Med. Chem., 2014, 57(2), 339
Patel P. R., Sun W., Kim M., Huang X. L., Sanderson P. E., Tanaka T. Q., McKew J. C., Simeonov A., Williamson K. C., Zheng W., Huang W. W., Bioorg. Med. Chem. Lett., 2016, 26(12), 2907
Zegzouti H., Zdanovskaia M., Hsiao K., Goueli S. A., Assay and Drug Development Technologies, 2009, 7(6), 560
Seixas J. D., Luengo-Arratta S. A., Diaz R., Saldivia M., Rojas-Barros D. I., Manzano P., Gonzalez S., Berlanga M., Smith T. K., Navarro M., Pollastri M. P., J. Med. Chem., 2014, 57(11), 4834
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by the Fund of Jilin University(China) Hi-Tech(Group) Co., Ltd.
Rights and permissions
About this article
Cite this article
Li, Y., Zhang, X., Niu, S. et al. Synthesis and biological activity of imidazo[4,5-c]quinoline derivatives as PI3K/mTOR inhibitors. Chem. Res. Chin. Univ. 33, 895–902 (2017). https://doi.org/10.1007/s40242-017-7074-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40242-017-7074-1